Robert Wessman, Chairman and CEO of Alvogen, will be a keynote speaker at the 4th Annual World Generic Medicines Congress. Read

Tomasz Czekala and Jerko Jaksic have been appointed to serve as key business leaders in Poland and Croatia. Read

Alvogen today announced that its subsidiary, Alvogen Romania, has launched generic versions of three oncology products: exemestane, irinotecan and letrozole. Read

Alvogen today announced its collaboration with the Massachusetts Institute of Technology (MIT) through its Industrial Liaison Program (ILP).  The program is industry's chief guide and gateway to the vast resources at MIT, a world leader in education and research. Read

Doug Drysdale, Alvogen’s CEO, has been named one of Pharmaceutical Executive’s emerging pharma leaders for 2011. Link to the full article Read

Peter Keil is the new regional manager for Alvogen in Asia and will lead the commercial activities for all countries in the region except China and India. Read

Robert Wessman, Executive Chairman of Alvogen will be a keynote speaker at the 5th Annual World Generic Medicines Congress Europe, in London.  Read

Scheusan has an outstanding track record in the generic industry after holding senior executive positions with large global generic companies. Read

- 180-day marketing exclusivity expected - U.S. brand sales in excess of US$1 billion - Complements a fast growing U.S. pipeline of over 70 drugs Read

 - Nitroglycerin patch includes small patch sizes and RSS barcoding Read

Alvogen, today announced that it has successfully closed a private placement financing. Read

Alvogen today announced that its subsidiary, Alvogen Romania has launched Clopidogrel (Vatoud 75mg). Read

Alvogen has opened a new research and development facility aimed at developing first-to-file and complex generic pharmaceutical products, including controlled release pharmaceuticals. Read

Alvogen today announced that it has entered into an agreement with Orchid Chemicals & Pharmaceuticals. Alvogen will market eight high potential oral products from Orchid in the US market, with ... Read

Alvogen Inc. (“Alvogen”), the US-based generic pharmaceuticals company, today announced that it has expanded its operations in India, by establishing own clinical research organization (“CRO”) and... Read

Alvogen Inc, the US-based generic pharmaceutical company, today announces that it has added to its Global Business Development and R&D teams. These appointments will further strengthen Alvogen’s capability to ... Read

Alvogen Inc. the US-based generic pharmaceutical company, today announces that three new top executives have joined its Executive Board. The new executives have an outstanding track record in the generic industry ... Read

Alvogen today announced that it has expanded operations in Eastern Europe and has opened an office in Bucharest, Romania. Read

Multinational pharmaceuticals company establishes foothold in critical Chinese market Read

As part of the agreement, Alvogen and Par have entered into a multi-year agreement for the development of several high-value, first-to-file generic product opportunities. Read